BACKGROUND AND OBJECTIVE: The major cause of failure in the management of retinoblastoma is the persistence/recurrence of vitreous seeds (VS). This study reports the efficacy and complications of standard lower-dose (20 µg) intravitreal melphalan for VS. PATIENTS AND METHODS: Retrospective review of all patients with active VS treated with lower-dose intravitreal melphalan (20 µg/0.1 mL) on a monthly basis until complete VS regression was achieved. RESULTS: A total of 14 injections were delivered to seven eyes of seven patients (range: 1-4; median: 2). At a median follow-up of 20 months (range: 12-32 months), complete regression of VS was achieved in all cases (100%), and globe salvage was achieved in six cases (86%). One eye required enucleation for solid tumor recurrence. Side effects of retinal pigment epithelium mottling at the site of injection was noted in two eyes (29%). CONCLUSION: The 2-year results of this study suggest that standard lower-dose (20 µg) intravitreal melphalan is safe and highly effective for the management of viable VS from retinoblastoma. Copyright 2015, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: The major cause of failure in the management of retinoblastoma is the persistence/recurrence of vitreous seeds (VS). This study reports the efficacy and complications of standard lower-dose (20 µg) intravitreal melphalan for VS. PATIENTS AND METHODS: Retrospective review of all patients with active VS treated with lower-dose intravitreal melphalan (20 µg/0.1 mL) on a monthly basis until complete VS regression was achieved. RESULTS: A total of 14 injections were delivered to seven eyes of seven patients (range: 1-4; median: 2). At a median follow-up of 20 months (range: 12-32 months), complete regression of VS was achieved in all cases (100%), and globe salvage was achieved in six cases (86%). One eye required enucleation for solid tumor recurrence. Side effects of retinal pigment epithelium mottling at the site of injection was noted in two eyes (29%). CONCLUSION: The 2-year results of this study suggest that standard lower-dose (20 µg) intravitreal melphalan is safe and highly effective for the management of viable VS from retinoblastoma. Copyright 2015, SLACK Incorporated.
Authors: Jesse L Berry; Liya Xu; A Linn Murphree; Subramanian Krishnan; Kevin Stachelek; Emily Zolfaghari; Kathleen McGovern; Thomas C Lee; Anders Carlsson; Peter Kuhn; Jonathan W Kim; David Cobrinik; James Hicks Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Albert Liao; Terry Hsieh; Jasmine H Francis; Jessica A Lavery; Audrey Mauguen; Scott E Brodie; David H Abramson Journal: Retina Date: 2021-01-01 Impact factor: 3.975